News | August 12, 2024
Lupin Q1 FY25 profit up 77% at Rs. 801 Cr
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Our centers are performing as expected or even better
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The company has seamlessly integrated the business acquired from Yash Pharma into Jagsonpal and are now confident of aligning the margins of the acquired business with that of Jagsonpal ahead of schedule
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Expect the international business including CDMO business to pick-up in the second half of the financial year
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Subscribe To Our Newsletter & Stay Updated
